Yescarta

UK rejects Gilead's CAR-T cancer cell therapy as too expensive
UK rejects Gilead's CAR-T cancer cell therapy as too expensive
Reuters
Yescarta
UK
Europe
CAR-T
NICE
Gilead Sciences
Flag link:
Kite Receives Positive Opinion from CHMP for Yescarta in Lymphoma
Kite Receives Positive Opinion from CHMP for Yescarta in Lymphoma
CP Wire
Kite Pharma
Gilead Sciences
EMA
CHMP
Yescarta
B-cell lymphoma
Flag link:
Could an old Amgen-developed RA drug make CAR-T treatments safer?
Could an old Amgen-developed RA drug make CAR-T treatments safer?
Fierce Biotech
CAR-T
cytokine release syndrome
Kymriah
Yescarta
Amgen
Kineret
Flag link:
Gilead finds new home in Europe for CAR-T manufacturing
Gilead finds new home in Europe for CAR-T manufacturing
Biopharma Dive
Gilead Sciences
Netherlands
Yescarta
drug manufacturing
Flag link:
New approval sets up CAR-T showdown for Gilead, Novartis
New approval sets up CAR-T showdown for Gilead, Novartis
Biopharma Dive
Kymriah
Novartis
cell therapy
Yescarta
Gilead Sciences
Flag link:
Medicare sets outpatient rate for Yescarta reimbursement
Medicare sets outpatient rate for Yescarta reimbursement
Reuters
Medicare
Yescarta
reimbursement
Gilead Sciences
Flag link:
5 Drugs That Are Critical for Gilead Sciences' Future
5 Drugs That Are Critical for Gilead Sciences' Future
Motley Fool
Gilead Sciences
Biktarvy
Yescarta
selonsertib
filgotinib
Epclusa
Flag link:
ICER declares costs of approved CAR-T therapies aligned with clinical benefit
ICER declares costs of approved CAR-T therapies aligned with clinical benefit
BioWorld
CAR-T
ICER
Gilead Sciences
Yescarta
Novartis
Kymriah
drug pricing
Flag link:
Beefing up its CAR-T pipeline, Gilead teams up with Pfizer on a lymphoma combo
Beefing up its CAR-T pipeline, Gilead teams up with Pfizer on a lymphoma combo
Endpoints
CAR-T
Gilead Sciences
Pfizer
utomilumab
Yescarta
large B-cell lymphoma
Flag link:
Kymriah, Yescarta found ‘cost-effective’ in treating cancer, despite high price
Kymriah, Yescarta found ‘cost-effective’ in treating cancer, despite high price
Endpoints
Kymriah
Yescarta
CAR-T
Novartis
Kite Pharma
Gilead Sciences
drug pricing
Flag link:
Is Gilead’s new CAR-T overpriced or is payer bureaucracy to blame for slow pickup?
Is Gilead’s new CAR-T overpriced or is payer bureaucracy to blame for slow pickup?
Fierce Pharma
Gilead Sciences
CAR-T
drug pricing
Yescarta
Flag link:
ASH 2017: CAR-T Wallops Blood Cancer
ASH 2017: CAR-T Wallops Blood Cancer
Motley Fool
ASH2017
CAR-T
gene therapy
Novartis
Kymriah
Yescarta
Gilead Sciences
Juno Therapeutics
JCAR017
Flag link:
ASH17: Benefit of Gilead's CAR-T remains durable over longer term
ASH17: Benefit of Gilead's CAR-T remains durable over longer term
BioPharma Dive
ASH17
Gilead Sciences
CAR-T
Yescarta
diffuse large B-cell lymphoma
Flag link:
Gilead Slaps Mega-Price on Its Newly Approved CAR-T
Gilead Slaps Mega-Price on Its Newly Approved CAR-T
Motley Fool
Gilead Sciences
CAR-T
drug pricing
Yescarta
Kite Pharma
Flag link:
Move over, Novartis: Kite and Gilead break into CAR-T market with early axi-cel nod
Move over, Novartis: Kite and Gilead break into CAR-T market with early axi-cel nod
Fierce Pharma
Gilead Sciences
Kite Pharma
Novartis
CAR-T
FDA
axi-cel
Yescarta
non-Hodgkin's lymphoma
large B-cell lymphoma
Flag link: